PMID- 34505736
OWN - NLM
STAT- MEDLINE
DCOM- 20221031
LR  - 20221031
IS  - 1470-8744 (Electronic)
IS  - 0885-4513 (Linking)
VI  - 69
IP  - 5
DP  - 2022 Oct
TI  - Liposomes: Ideal drug delivery systems in breast cancer.
PG  - 1867-1884
LID - 10.1002/bab.2253 [doi]
AB  - Breast cancer (BC) has been recognized as the most common type of cancer in 
      females across the world, accounting for 12% of each cancer case. In this sense, 
      better diagnosis and screening have been thus far proven to contribute to higher 
      survival rates. Moreover, traditional (or standard) chemotherapy is still known 
      as one of the several prominent therapeutic options available, though it suffers 
      from unsuitable cell selectivity, severe consequences, as well as resistance. In 
      this regard, nanobased drug delivery systems (DDSs) are likely to provide 
      promising grounds for BC treatment. Liposomes are accordingly effective 
      nanosystems, having the benefits of multiple formulations verified to treat 
      different diseases. Such systems possess specific features, including smaller 
      size, biodegradability, hydrophobic/hydrophilic characteristics, 
      biocompatibility, lower toxicity, as well as immunogenicity, which can all lead 
      to considerable efficacy in treating various types of cancer. As chemotherapy 
      uses drugs to target tumors, generates higher drug concentrations in tumors, 
      which can provide for their slow release, and enhances drug stability, it can be 
      improved via liposomes in DDSs for BC treatment. Therefore, the present study 
      aims to review the existing issues regarding BC treatment and discuss 
      liposome-based targeting in order to overcome barriers to conventional drug 
      therapy.
CI  - (c) 2021 International Union of Biochemistry and Molecular Biology, Inc.
FAU - Forouhari, Sedighe
AU  - Forouhari S
AD  - Infertility Research Center, Research Center of Quran, Hadith, and Medicine, 
      Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Beygi, Zahra
AU  - Beygi Z
AD  - Department of Nursing and Midwife, Maybod Branch, Islamic Azad University, 
      Maybod, Iran.
FAU - Mansoori, Zahra
AU  - Mansoori Z
AD  - Faculty of Educational Sciences and Psychology, Department of Sports Sciences, 
      Shiraz University, Shiraz, Iran.
FAU - Hajsharifi, Sara
AU  - Hajsharifi S
AD  - Student Research Committee, Department of Midwifery, Fatemeh (PBUH) School of 
      Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Heshmatnia, Fatemeh
AU  - Heshmatnia F
AD  - Student Research Committee, Department of Midwifery, Fatemeh (PBUH) School of 
      Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Gheibihayat, Seyed Mohammad
AU  - Gheibihayat SM
AUID- ORCID: 0000-0002-1378-118X
AD  - Department of Medical Biotechnology, School of Medicine, Shahid Sadoughi 
      University of Medical Sciences, Yazd, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210921
PL  - United States
TA  - Biotechnol Appl Biochem
JT  - Biotechnology and applied biochemistry
JID - 8609465
RN  - 0 (Liposomes)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Liposomes/therapeutic use
MH  - *Breast Neoplasms/drug therapy
MH  - Drug Delivery Systems
OTO - NOTNLM
OT  - breast cancer
OT  - drug delivery system
OT  - liposome
OT  - tumor
EDAT- 2021/09/11 06:00
MHDA- 2022/11/01 06:00
CRDT- 2021/09/10 08:44
PHST- 2021/03/06 00:00 [received]
PHST- 2021/09/06 00:00 [accepted]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2022/11/01 06:00 [medline]
PHST- 2021/09/10 08:44 [entrez]
AID - 10.1002/bab.2253 [doi]
PST - ppublish
SO  - Biotechnol Appl Biochem. 2022 Oct;69(5):1867-1884. doi: 10.1002/bab.2253. Epub 
      2021 Sep 21.